Navigation Links
Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

fecting our PolyHeme red blood cell substitute product. These forward-looking statements are identified by the use of such terms as "intends," "expects," "plans," "estimates," "anticipates," "should," "believes" and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various factors and possible events, including the possibility that since the data from our Phase III clinical trial have not been submitted to, or reviewed by, FDA, they may not be sufficient to demonstrate the safety or effectiveness of PolyHeme, our ability to obtain FDA approval to market PolyHeme commercially, our ability to obtain priority review, the availability of capital to finance our clinical trials and ongoing business operations, our ability to obtain adequate supplies of raw materials and to manufacture PolyHeme in commercial quantities, our ability to market PolyHeme successfully, the possibility that competitors will develop products that will render PolyHeme obsolete or non-competitive, our ability to protect our intellectual property rights, the outcome of certain governmental inquiries and purported class action lawsuit as described in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, the possibility that we may be subject to product liability claims and other legal actions, our dependency on a limited number of key personnel, the uncertainty of third party reimbursement for our product and other risks and uncertainties described from time to time in our periodic reports filed with the Securities and Exchange Commission, including our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. These forward-looking statements speak only as of the date of this press release. We do not undertake any obligation to update or publicly release any revisions to forward-looking stat
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among ... consolidation of localization purchasing in 2015, says Moravia ... to a recent study by market research firm Common ... single-source solution for their translation and localization needs. "From ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition ... & by End User - Global Forecast to 2019" ... diagnostics market is valued at $1,228.58 million in 2014 and ... reach $2,230.72 million by 2019. Allergy diagnostics is used to ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Robbins & Myers, Inc. (NYSE: RBN ) ... second quarter ending February 28, 2010 , before the market ... is scheduled for Wednesday, March 24, 2010 , at ... Officer, and Christopher M. Hix , Vice President and Chief ...
... March 10 CVS Caremark Corporation (NYSE: CVS ) today announced that its Board of Directors has approved a quarterly dividend of $0.0875 per share on ... ... ... ...
Cached Medicine Technology:Robbins & Myers to Release Second Quarter Fiscal 2010 Financial Results 2CVS Caremark Corporation Announces Quarterly Dividend 2
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Southwestern Medical Center maternal-fetal specialists have confirmed a potential ... risk for hepatitis B, a health problem that affects ... vaccination schedule for high-risk pregnant women was found effective ... Obstetrics & Gynecology . While the normal three-shot ...
... , MONDAY, June 27 (HealthDay News) -- Certain groups ... poorer outcomes and higher death rates than those treated ... study. Nearly five million people live in U.S. ... Northern Mariana Islands and the U.S. Virgin Islands, according ...
... childhood cancer survivors found that the first cancer is ... forms of the disease for about 10 percent of ... in the federally funded Childhood Cancer Survivor Study (CCSS). ... reported that 1,382, or 9.6 percent, of survivors developed ...
... 27 (HealthDay News) -- Uncovering some science behind the type ... and Canadian researchers reports that a woman can tell whether ... face when she is ovulating. Women also appear to ... they start to harbor romantic notions or mating aspirations, the ...
... Scientists have long known that, to form tissue structures ... the other cells, matrix, and signals in their environment. But ... to distinguish between normal and pathological behaviors. A team of ... to evaluate human stem cells using cell micropatterning a ...
... HealthDay Reporter , MONDAY, June 27 (HealthDay News) -- ... both by violent media content and greater evening use of ... Reviewing parent surveys and media diaries from 617 preschoolers, Seattle ... was linked to a significant jump in sleep problems, as ...
Cached Medicine News:Health News:Stepped-up vaccine series for hepatitis B is effective during pregnancy 2Health News:Childhood cancer survivors are at high risk for multiple tumors as they age 2Health News:Childhood cancer survivors are at high risk for multiple tumors as they age 3Health News:Does Ovulation Boost a Woman's 'Gaydar'? 2Health News:Tiny cell patterns reveal the progression of development and disease 2Health News:Tiny cell patterns reveal the progression of development and disease 3Health News:Content, Timing of TV Can Take Toll on Kids' Sleep 2Health News:Content, Timing of TV Can Take Toll on Kids' Sleep 3
Inquire...
Inquire...
... in four convenient formats to meet all ... custom draping for any surgical procedure. All ... billowing up. , ,The precision, die-cut holes ... layer is soft against the patient's skin. ...
For use with WarmTouch® Warming Blankets for the prevention or treatment of hypothermia...
Medicine Products: